Histrelin

Summary

Histrelin is a synthetic non‑peptide analogue of gonadotropin‑releasing hormone (GnRH) formulated as a subcutaneous, diffusion‑controlled implant. It is approved for the treatment of advanced prostate cancer and for central precocious puberty (CPP) in children. The implant releases histrelin continuously, providing long‑term suppression of the hypothalamic‑pituitary‑gonadal axis, which lowers testosterone in men and halts pubertal development in youngsters.

Mechanism of Action

Histrelin binds to GnRH receptors on pituitary gonadotrophs. Continuous exposure initially stimulates luteinising hormone (LH) and follicle‑stimulating hormone (FSH) release, but rapidly desensitises the receptor and down‑regulates signalling, leading to a profound fall in LH/FSH secretion. The downstream effect is a marked reduction in gonadal steroid production (testosterone in males, estradiol in females), effectively inducing a medical castration or pubertal arrest. The implant’s steady‑state release maintains drug levels sufficient for this chronic suppression.

What the Research Shows

Phase II and III trials in men with advanced prostate cancer reported that a 50‑mg subcutaneous histrelin implant lowered serum testosterone to castrate levels (≤50 ng/dL) within four weeks, with 99‑100 % of patients maintaining suppression for the full year of treatment. A transient testosterone surge occurred after the first implant but not after replacement. In pediatric populations with central precocious puberty, a single 50‑mg implant produced profound suppression of the hypothalamic‑pituitary‑gonadal axis within one month, arresting puberty, slowing skeletal advancement and increasing predicted adult height. Suppression has been shown to persist for up to two years from a single implant. Early small studies using daily sub‑cutaneous doses (8‑10 µg/kg) demonstrated pituitary desensitisation within three months. Across studies, the implant was generally well tolerated, with few discontinuations.

Reported Benefits

Clinical data demonstrate that histrelin reliably produces medical castration in men with advanced prostate cancer, maintaining testosterone at castrate levels for at least one year without the need for repeated injections. In children with CPP, the implant halts pubertal progression, reduces bone age advancement and can improve predicted adult stature, with a single device lasting up to two years, reducing treatment burden. The subcutaneous, removable format offers convenience compared with monthly depot injections.

Limitations of the Evidence

Evidence for histrelin in prostate cancer derives mainly from open‑label phase II/III studies lacking active comparators, limiting direct efficacy comparisons. Pediatric data, while promising, come from relatively small cohorts and lack long‑term follow‑up on final adult height. Implant removal can be problematic; about a quarter of devices break during extraction. Information on recovery of the hypothalamic‑pituitary‑gonadal axis after explantation is limited and shows wide individual variability. Adverse‑event reporting is sparse, focusing on injection‑site reactions, leaving uncertainty about less common systemic effects.

Safety Considerations

The most frequently reported adverse effect is a local skin reaction at the implantation site. In prostate cancer trials, the implant was generally well tolerated, with no premature discontinuations; a transient testosterone surge after the initial placement was noted but did not result in clinical worsening. Hormone suppression can cause symptoms typical of medical castration (e.g., hot flashes, decreased libido), although these were not detailed in the abstracts. Breakage of the implant during removal occurs in roughly 25 % of cases, requiring careful surgical technique. Caution is advised in patients where long‑term gonadal hormone depletion may be undesirable.

How It Is Administered

Histrelin is supplied as a 50‑mg subcutaneous reservoir implant that releases drug at a constant rate. The device is placed under local anesthesia in an outpatient setting, typically in the upper arm or abdomen, and can remain in situ for up to one year for prostate cancer or up to two years for central precocious puberty. Removal is performed surgically; the implant may be replaced without loss of hormonal suppression.

Routes of Administration

Goals & Uses

• Palliative treatment of advanced prostate cancerOncologyHigh
• Prostate cancerOncologyHigh
• Testosterone suppression in transgender womenGender Affirming CareModerate
• Central precocious pubertyPediatric EndocrinologyHigh
• Endometriosis managementGynecologyLow
• Treatment of central precocious puberty (CPP)Pediatric EndocrinologyHigh
• EndometriosisGynecologyModerate

Contraindications

• Hypersensitivity to histrelin, GnRH, or GnRH analoguesAllergyHigh
• Known hypersensitivity to histrelin or excipientsAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Women of childbearing potential not using effective contraceptionReproductiveHigh

Adverse Effects

• Implant site reactionsLocal/dermatologicCommon
• Testosterone flare (initial)EndocrineCommon
• Decreased bone mineral densityMusculoskeletalCommon
• Decreased libidoSexual / EndocrineCommon
• Hot flashesEndocrine / VasomotorCommon
• Bone mineral density lossSkeletalUncommon
• Sexual dysfunction / decreased libidoEndocrine/sexualCommon
• Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
• QT prolongationCardiovascularUncommonExtended QT interval on ECG
• Hot flushes / hot flashesEndocrine/vasomotorCommon

Drug Interactions

• Anticoagulants (e.g., warfarin)Moderate
• Estrogen replacement therapyModerate
• Insulin / antidiabetic agentsModerate
• QT-prolonging agents (e.g., antiarrhythmics, antipsychotics, fluoroquinolones)High
• CYP450 inducers (e.g., rifampin)Low

Population Constraints

• Patients with osteoporosis or high fracture riskMusculoskeletalRelative
• Adult males with advanced prostate cancerAgeRelative
• Pediatric patients with central precocious pubertyAgeRelative
• Patients with cardiovascular diseaseComorbidityRelative
• Patients with spinal metastases or urinary obstruction (prostate cancer)Disease SpecificRelative
• Pediatric patients (CPP)AgeRelative

Regulatory Status

• European UnionApprovedApproved: central precocious puberty, endometriosisAvailable under the trade name Vantas/Supprelin in select EU member states.
• United StatesApprovedApproved: advanced prostate cancer, central precocious puberty, endometriosisVantas® (prostate cancer) and Supprelin LA® (CPP, endometriosis) are FDA‑approved.
• United KingdomUnknownNot listed as a standard MHRA-approved product; other GnRH agonists (leuprolide, goserelin, triptorelin) are more commonly used in the UK.

Approved in the United States (Vantas® for prostate cancer; Supprelin LA® for CPP and endometriosis). Marketed as an implant delivering drug over 12 months. Not available as an oral formulation.

Evidence & Sources

• Histrelin: in advanced prostate cancer
  Journal ArticleModerateDeeks ED2010-01-01T00:00:00.000000Z
• Experience with the Histrelin Implant in Pediatric Patients
  Journal ArticleModerateEugster EA2016-01-01T00:00:00.000000Z
• Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty
  Journal ArticleModerateBarradell LB, McTavish D1993-01-01T00:00:00.000000Z
• Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424
  Journal ArticleModerate2005-01-01T00:00:00.000000Z

Frequently Asked Questions